Results from AGMT_MM-1 published
In September, two publications on the AGMT_MM-1 study were published....
Prof. Dr. Richard Greil
Head of the IIIrd Medical Department, University Hospital Salzburg, Paracelsus Medical University, Salzburg Cancer Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria
Prof. Peter Schmid FRCP MD PhD
Centre Lead, Centre for Experimental Cancer Medicine, Director, Breast Cancer, St Bartholomew, Hospital London, London, United Kingdom
Karen Willard-Gallo MD PhD
Head, Molecular Immunology Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
Dr. Roberto Salgado
Department of Pathology, GZA-ZNA Antwerp, Belgium; Division of Research, Peter Mac Callum Cancer Center, Melbourne, Australia
Cecilia Garlanda PhD
Associate Professor of Clinical Pathology, Department of Biomedical Sciences, Humanitas University, Head of Laboratory of Experimental Immunopathology, Humanitas Research Hospital, Milan, Italy
Marie-Agnès Doucey PhD MER
Project Leader,Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research, Lausanne Branch, Lausanne, Switzerland
Maria Vittoria Dieci MD
Assistant Professor, Department of Surgery, Oncology and Gastroenterology, Istituto Oncologico Veneto IRCCS, Division of Medical Oncology 2, University of Padova, Padova, Italy
Prof. Richard Kennedy MD PhD
McClay Professor of Medical Oncology, Queen‘s University of Belfast, Global VP and Medical Director Almac Diagnostics
Chiara Pozzi PhD
Staff scientist, Lab. Mucosal Immunology and Microbiota, Humanitas Clinical and Research Center, Milan, Italy
Shom Goel B Med Sci MBBS FRACP PhD
Instructor in Medicine, Dana-Farber Cancer Institute, Boston MA, USA
Prof. Dr. Fritz Aberger
Molecular Cancer and Stem Cell Research, Lab Department of Molecular Biology, University of Salzburg, Cancer Cluster Salzburg (CCS), Salzburg, Austria
Dr. Gabriel Rinnerthaler
IIIrd Medical Department, University Hospital Salzburg, Paracelsus Medical University, Salzburg Cancer, Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria
Marco Gerlinger MD FRCP
Medical Oncologist and Research Group Leader, Translational Oncogenomics Laboratory, Centre for Evolution and Cancer, Institute of Cancer Research, London, United Kingdom
Prof. Dr. Barbara Seliger
Director of the Institute for Medical Immunology, Martin Luther University, Medical Faculty, Halle, Germany
Dr. Simon P. Gampenrieder
IIIrd Medical Department, University Hospital Salzburg, Paracelsus Medical University, Salzburg Cancer Research Institute (SCRI), Cancer Cluster Salzburg (CCS), Salzburg, Austria
Dr. Mathilde Jalving
Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
Dr. Dominik Berzaczy
Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
Cornelia Quadt MD
Sr. Clinical Program Leader, Translational Clinical Oncology, Novartis Institute for Biomedical Research, Novartis Campus, Basel, Switzerland
Prof. Dr. Udo Gaipl
Head of Radiation Immunobiology, Universitätsklinikum Erlangen, Department of Radiation Oncology, Erlangen, Germany
13:30 – 13:35 Welcome and introduction
Richard Greil, Salzburg
13:35 – 14:00 Current evidence of immunotherapy in breast cancer
Regula Deurloo, Senior Scientist Group Lead, Roche, Basel (stand-in for Peter Schmid)
14:00 – 16:15 Adaptive Immunity
Chair: Richard Greil, Karen Willard-Gallo
Tertiary Lymphoid Structures (TLS)
Karen Willard-Gallo (Brussels)
Change of the immune infiltrate during treatment
Roberto Salgado (Brussels)
Cancer-related inflammation
Cecilia Garlanda (Milan)
TIE-2-expressing monocytes
Marie-Agnes Doucey (Lausanne)
Panel discussion
17:00 – 18:30 Influence on Immunogenicity
Chair: Richard D. Kennedy, Shom Goel
Influence on immunogenicity by DNA damage
Richard D. Kennedy (Belfast)
Influence on immunogenicity by the microbiota
Chiara Pozzi (Milan)
Influence on immunogenicity by targeting CDK4/6
Shom Goel (Boston MA)
08:30 – 09:30 Heterogeneity & Immune Escape
Chair: Fritz Aberger, Gabriel Rinnerthaler
Neoantigene heterogeneity
Marco Gerlinger (London)
Immune escape in breast cancer
Barbara Seliger (Halle)
09:30 – 10:30 Imaging
Chair: Simon P. Gampenrieder, Mathilde Jalving
Imaging techniques in immuno-oncology
Dominik Berzaczy (Vienna)
iRECIST 1.1
Mathilde Jalving (Groningen, NL)
11:15 – 13:00 New Treatment Approaches
Chair: Richard Greil, Udo Gaipl
Targeting the adenosine pathway
Cornelia Quadt (Basel, Novartis)
Immunomodulation by radiotherapy
Udo Gaipl (Erlangen)
Panel discussion & Closing remarks
Richard Greil (Salzburg)
3rd SALZBURG BREAST CANCER TALK – Mastering translational Immuno-Oncology has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 7 European CME credits (ECMEC®s).
Prof. Dr. Richard Greil
Dr. Simon P. Gampenrieder
Dr. Gabriel Rinnerthaler
Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT)
in Kooperation mit
Cancer Cluster Salzburg | www.cancercluster-salzburg.at
endorsed by ECCO – European CanCer Organisation | www.ecco-org.eu
In September, two publications on the AGMT_MM-1 study were published....
01.- 02.03.2019 Salzburg — MASTERING TRANSLATIONAL IMMUNO-ONCOLOGY...
02.- 03.03.2018 Salzburg — MASTERING TRANSLATIONAL IMMUNO-ONCOLOGY...
10.- 11.02.2017 Salzburg — MASTERING TRANSLATIONAL IMMUNO-ONCOLOGY...